Sangamo Therapeutics, Inc. reported that it submitted amended July and August monthly operating reports and a September report in its Chapter 11 case. The September report lists $161.0 million in cash sales price for assets sold outside the ordinary course, $32.2 million in related payments to third parties, and $128.8 million in net cash proceeds. It also records $161.1 million in gross income/sales and $143.8 million in net profit for September.
At September 30, total assets were $264.2 million, total liabilities were $82.9 million, ending equity/net worth was $181.3 million, and ending cash was $138.5 million. The report lists 13 full-time employees, compared with 74 as of the date of the order for relief. July and August reports recorded net losses of $11.2 million and $14.4 million, respectively. The monthly reports are unaudited, were not prepared under U.S. GAAP, and are subject to future adjustment and reconciliation; Sangamo cautioned they may not be complete or indicative of future results. SGMOQ was delisted effective October 17, 2026, and currently trades on the OTC Expert Market on an unsolicited quotes only basis. Sangamo cautioned that trading during Chapter 11 is highly speculative and poses substantial risks.
Sangamo Therapeutics (SGMOQ) furnished its August 2026 Chapter 11 monthly operating report, covering August 1 through August 31. It lists $10,145,433 in cash receipts, $3,826,691 in disbursements and an ending cash balance of $23,225,696. Gross income/sales was $430,190, and the reported net loss was $14,449,029.
During August, Sangamo drew $7 million under the Replacement DIP Facility. It also completed two equipment sales: equipment and office furniture sold to Surplus Solutions, LLC for $2,300,000 plus other consideration, and lab equipment sold to Future Solution Investments LLC for a $250,000 offset against DIP Obligations plus other consideration. Both sales closed on or about August 20, 2026.
The report is unaudited, was not prepared in accordance with U.S. GAAP and is subject to future adjustment. Sangamo’s common stock was suspended from Nasdaq and was trading on the OTC Pink Limited Market as SGMOQ; delisting and deregistration under Section 12(b) are effective October 17, 2026.
Sangamo Therapeutics, Inc.'s common stock is the subject of a Nasdaq Stock Market LLC Form 25 notification concerning removal from listing and/or registration under Section 12(b). The notice states that Nasdaq complied with its rules to strike the class from listing and/or withdraw registration, and recites the issuer's compliance with requirements governing voluntary withdrawal.
SANGAMO THERAPEUTICS, INC. (SGMOQ) has completed a court‑supervised sale of all assets primarily related to its ST‑920 Fabry disease gene therapy program to PTC Therapeutics, Inc. The transaction, conducted during Sangamo’s Chapter 11 proceedings, closed on September 17, 2026.
Under the Asset Purchase Agreement, Sangamo receives $111,000,000 in cash at closing, plus up to an additional $100,000,000 in contingent milestone payments, and PTC assumes certain specified liabilities. Sangamo discloses that its common stock has been delisted from the Nasdaq Capital Market, now trades on the OTC Basic Market as “SGMOQ,” and that trading during the Chapter 11 case is highly speculative, with potential recoveries for shareholders uncertain.
SANGAMO THERAPEUTICS, INC. (SGMOQ) completed a court‑approved sale of key technology assets to Eli Lilly and Company for $50 million in cash plus the assumption of certain specified liabilities. The transaction, effective September 4, 2026, transfers Sangamo’s AAV capsid engineering platform (including STAC‑BBB), zinc finger protein platform, Modular Integrase genome editing platform, the ST‑506 prion disease program, related intellectual property, and certain rights to receive future milestone and royalty payments under specified out‑licensing agreements.
Sangamo has been operating as a debtor‑in‑possession under Chapter 11 since filing its voluntary petition on June 23, 2026. A court‑supervised auction on August 10, 2026 selected Lilly as the successful bidder, and a Sale Order authorizing the sale was entered on August 20, 2026. The company’s common stock was suspended from trading on Nasdaq on May 5, 2026 and now trades on the OTCID Basic Market under the symbol SGMOQ.
The company filed a monthly operating report for July 2026 with the Bankruptcy Court, furnished as Exhibit 99.1, and emphasizes that this report is unaudited, not prepared under U.S. GAAP, limited in scope, and intended solely to comply with bankruptcy reporting requirements. Sangamo cautions that trading in its common stock during the Chapter 11 Case is highly speculative and poses substantial risks, and that market prices may bear little or no relationship to any eventual recovery, if any, by stockholders.
SANGAMO THERAPEUTICS, INC. (SGMOQ) has agreed to sell substantially all assets related to its Fabry disease gene therapy candidate ST-920 to PTC Therapeutics, Inc. under an Asset Purchase Agreement entered into on August 25, 2026, in the context of Sangamo’s ongoing Chapter 11 case in Delaware.
The Transaction provides $111,000,000 in cash at closing plus up to $100,000,000 in milestone payments tied to FDA approvals, and includes PTC’s assumption of specified liabilities. Closing remains subject to multiple conditions, including a Sale Order from the Bankruptcy Court, HSR clearance, a scheduled hearing on September 10, 2026, and satisfaction of employee retention requirements, with an outside closing date of October 15, 2026.
Sangamo Therapeutics, Inc. filed a Form 12b-25 stating it cannot file its Form 10-Q for the quarter ended June 30, 2026 by the deadline or the five-day extension without unreasonable effort or expense. The company is operating under Chapter 11 bankruptcy protection after filing a voluntary petition on June 23, 2026 in the U.S. Bankruptcy Court for the District of Delaware, case number 26-10989, and continues to function as a debtor in possession.
Management and limited finance staff are focused on bankruptcy-related requirements, and the Audit Committee terminated Ernst & Young LLP as independent auditor effective June 25, 2026, with no new firm engaged. The company expects its results for the three and six months ended June 30, 2026 to differ significantly from the prior year due to Chapter 11 costs, paused programs, workforce reductions, and potential additional asset impairments, and cannot yet estimate these charges. Its common stock has been suspended from Nasdaq, now trades on the OTCID Basic Market under the symbol SGMOQ, and the company warns that trading is highly speculative and that market prices may bear little or no relationship to any eventual recovery in the Chapter 11 case.
Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 38,860,819 shares of Sangamo Therapeutics, Inc. common stock, representing 9.38% of the outstanding class as of June 30, 2026. They report shared voting and dispositive power over all of these shares and no sole voting or dispositive power.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the same securities.
Sangamo Therapeutics, Inc. has concluded a court-supervised Section 363 auction in its Chapter 11 case, selecting winning bids from PTC Therapeutics and Eli Lilly and Company. The bids total approximately $163.55 million in cash at closing, plus potential future milestone payments of up to $100 million.
The asset sales cover Sangamo’s Fabry disease program, prion disease program, and its capsid delivery, zinc finger and modular integrase (MINT) platforms. The transactions remain subject to final approval by the U.S. Bankruptcy Court for the District of Delaware, required regulatory clearances including under the Hart‑Scott‑Rodino Act, and other customary closing conditions.
Sale hearings are expected in the third quarter of 2026, with the Lilly transaction anticipated to close on or about September 4, 2026, and the PTC transaction to close after completion of Hart‑Scott‑Rodino review. Sangamo continues to solicit offers for remaining assets, including programs ST‑503 and giroctocogene fitelparvovec and its cell therapy and T‑Reg assets.
Sangamo Therapeutics, Inc. reports initial Chapter 11 operating metrics for the period June 1–30, 2026, furnished via a monthly operating report. The company previously filed a voluntary Chapter 11 petition on June 23, 2026 in the District of Delaware.
During the month, Sangamo drew $10,500,000 under a senior secured superpriority debtor-in-possession term loan facility, driving total cash receipts to $10,503,072 against disbursements of $977,931. Cash increased from $4,857,102 to $14,382,243.
The report lists total assets of $153,087,245 and total liabilities of $89,151,054, including $10,987,803 of postpetition debt and $78,129,568 of prepetition unsecured debt. For the period, Sangamo recorded a net loss of $3,755,058, including $2,010,335 of reorganization items.
The company cautions that the MOR is unaudited, not prepared under U.S. GAAP, subject to change, and limited to bankruptcy reporting needs. It also warns that trading in its common stock, now quoted OTC under “SGMOQ” following Nasdaq suspension and delisting notice, is highly speculative and that trading prices may bear little or no relationship to any eventual recovery in the Chapter 11 case.